Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QCZ484 OLE in Hypertensive Patients
NCT07543120Phase 2Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Primary completion
- May 2031
- Modality
- RNA Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of QCZ484 in hypertension (HTN), sponsored by Novartis. Primary endpoint: Number of participants with Adverse Events at 66 months. Started May 2026; status: recruiting.
02
Drugs
QCZ484
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07543120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543120.